Internal cleavage and synergy with twisted gastrulation enhance BMP inhibition by BMPER.


Journal

Matrix biology : journal of the International Society for Matrix Biology
ISSN: 1569-1802
Titre abrégé: Matrix Biol
Pays: Netherlands
ID NLM: 9432592

Informations de publication

Date de publication:
04 2019
Historique:
received: 23 05 2018
revised: 13 08 2018
accepted: 16 08 2018
pubmed: 21 8 2018
medline: 3 8 2019
entrez: 21 8 2018
Statut: ppublish

Résumé

Bone morphogenetic proteins (BMPs) are essential signalling molecules involved in developmental and pathological processes and are regulated in the matrix by secreted glycoproteins. One such regulator is BMP-binding endothelial cell precursor-derived regulator (BMPER) which can both inhibit and enhance BMP signalling in a context and concentration-dependent manner. Twisted gastrulation (Tsg) can also promote or ablate BMP activity but it is unclear whether Tsg and BMPER directly interact and thereby exert a synergistic function on BMP signalling. Here, we show that human BMPER binds to Tsg through the N-terminal BMP-binding region which alone more potently inhibits BMP-4 signalling than full-length BMPER. Additionally, BMPER and Tsg cooperatively inhibit BMP-4 signalling suggesting a synergistic function to dampen BMP activity. Furthermore, full-length BMPER is targeted to the plasma membrane via binding of its C-terminal region to cell surface heparan sulphate proteoglycans but the active cleavage fragment is diffusible. Small-angle X-ray scattering and electron microscopy show that BMPER has an elongated conformation allowing the N-terminal BMP-binding and C-terminal cell-interactive regions to be spatially separated. To gain insight into the regulation of BMPER bioavailability by internal cleavage, a disease-causing BMPER point mutation, P370L, previously identified in the acid-catalysed cleavage site, was introduced. The mutated protein was secreted but the mutation prevented intracellular cleavage resulting in a lack of bioactive cleavage fragment. Furthermore, mutant BMPER was extracellularly cleaved at a downstream site presumably becoming available due to the mutation. This susceptibility to extracellular proteases and loss of bioactive N-terminal cleavage fragment may result in loss of BMPER function in disease.

Identifiants

pubmed: 30125619
pii: S0945-053X(18)30206-3
doi: 10.1016/j.matbio.2018.08.006
pmc: PMC6456722
pii:
doi:

Substances chimiques

BMP4 protein, human 0
BMPER protein, human 0
Bone Morphogenetic Protein 4 0
Carrier Proteins 0
Proteins 0
Recombinant Proteins 0
TWSG1 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

73-86

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R008221/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/L00612X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 088785/Z/09/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L011840/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N015398/1
Pays : United Kingdom

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Biophys J. 1999 Jun;76(6):2879-86
pubmed: 10354416
Biophys J. 2000 Mar;78(3):1606-19
pubmed: 10692345
Development. 2001 Nov;128(22):4439-47
pubmed: 11714670
Eur Biophys J. 2001 Oct;30(6):457-62
pubmed: 11718300
J Biol Chem. 2002 Feb 15;277(7):4883-91
pubmed: 11729207
Dev Dyn. 2004 Jul;230(3):434-45
pubmed: 15188429
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Thromb Haemost. 2005 Oct;94(4):713-8
pubmed: 16270622
Development. 2006 Mar;133(5):801-11
pubmed: 16439480
J Struct Biol. 2007 Jan;157(1):38-46
pubmed: 16859925
Development. 2006 Nov;133(22):4463-73
pubmed: 17035289
J Biol Chem. 2007 Jul 6;282(27):20002-14
pubmed: 17483092
Dev Cell. 2008 May;14(5):739-50
pubmed: 18477456
Dev Cell. 2008 Jun;14(6):940-53
pubmed: 18539121
Dev Cell. 2008 Aug;15(2):248-60
pubmed: 18694564
Circ Res. 2008 Oct 10;103(8):804-12
pubmed: 18787191
Dev Biol. 2008 Nov 1;323(1):6-18
pubmed: 18789316
J Cell Biol. 2009 Feb 23;184(4):597-609
pubmed: 19221194
Eur Biophys J. 2010 Feb;39(3):423-35
pubmed: 19234696
Biochem Biophys Res Commun. 2009 Jul 24;385(2):215-9
pubmed: 19450552
Dev Biol. 2010 Jan 15;337(2):405-14
pubmed: 19914233
Macromol Biosci. 2010 Jul 7;10(7):746-53
pubmed: 20480513
Am J Hum Genet. 2010 Oct 8;87(4):532-7
pubmed: 20869035
PLoS One. 2010 Sep 23;5(9):e12846
pubmed: 20886103
Annu Rev Genet. 2011;45:357-77
pubmed: 21942367
PLoS One. 2012;7(11):e50300
pubmed: 23209700
PLoS One. 2013;8(4):e60423
pubmed: 23573253
J Cell Sci. 2013 Jul 15;126(Pt 14):3082-94
pubmed: 23641068
Science. 2013 Jul 5;341(6141):77-80
pubmed: 23744777
J Synchrotron Radiat. 2013 Jul;20(Pt 4):660-4
pubmed: 23765312
Wiley Interdiscip Rev Dev Biol. 2013 Jan-Feb;2(1):47-63
pubmed: 23799630
Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):13063-8
pubmed: 25157165
J Appl Crystallogr. 2012 Mar 15;45(Pt 2):342-350
pubmed: 25484842
Methods Enzymol. 2015;558:363-390
pubmed: 26068747
Orphanet J Rare Dis. 2016 Jan 04;11:1
pubmed: 26728142
Matrix Biol. 2016 Sep;55:49-62
pubmed: 26829466
Matrix Biol. 2017 Jan;57-58:311-323
pubmed: 27609403
J Appl Crystallogr. 2009 Apr 1;42(Pt 2):342-346
pubmed: 27630371
Sci Rep. 2016 Oct 25;6:35956
pubmed: 27779234
J Appl Crystallogr. 2017 Jun 26;50(Pt 4):1212-1225
pubmed: 28808438
Matrix Biol. 2018 Nov;73:77-104
pubmed: 29524630

Auteurs

Michael P Lockhart-Cairns (MP)

Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK; Diamond Light Source, Harwell Science and Innovation Campus, Didcot, UK.

Karen Tzia Wei Lim (KTW)

Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.

Alexandra Zuk (A)

Center for Biochemistry, Medical Faculty, University of Cologne, Germany.

Alan R F Godwin (ARF)

Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.

Stuart A Cain (SA)

Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK.

Gerhard Sengle (G)

Center for Biochemistry, Medical Faculty, University of Cologne, Germany; Center for Molecular Medicine, University of Cologne, Germany.

Clair Baldock (C)

Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, UK. Electronic address: clair.baldock@manchester.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH